Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine

OBJECTIVE: To assess long‐term (up to 2 years) efficacy, tolerability, and safety of erenumab for the prevention of episodic migraine (EM) in Japanese patients. BACKGROUND: Previously published results from the double‐blind treatment phase (DBTP) of a phase 2 clinical study have demonstrated the eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakai, Fumihiko, Takeshima, Takao, Tatsuoka, Yoshihisa, Hirata, Koichi, Cheng, Sunfa, Numachi, Yotaro, Peng, Cheng, Xue, Fei, Mikol, Daniel D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251924/
https://www.ncbi.nlm.nih.gov/pubmed/33764538
http://dx.doi.org/10.1111/head.14096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251924/
https://www.ncbi.nlm.nih.gov/pubmed/33764538
http://dx.doi.org/10.1111/head.14096

Ejemplares similares